Explore

Trendline Trendline
Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline

Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline

Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline
Trendline Trendline
Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition

Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition

Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition
Reuters Reuters
Gilead to buy Germany's Tubulis for up to $5 billion to boost cancer pipeline

Gilead to buy Germany's Tubulis for up to $5 billion to boost cancer pipeline

April 7 (Reuters) - Gilead said on Tuesday it would acquire private Germany-based Tubulis GmbH for up to $5 billion, as the U.S. drugmaker looks to boost its pipeline with a lucrative class of experimental cancer drugs referred to as "guided missiles".
Trendline Trendline
Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio

Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio

Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio
Trendline Trendline
Gilead Acquires Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline

Gilead Acquires Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline

Gilead Acquires Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline
Trendline Trendline
Gilead Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities
Trendline Trendline
Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities

Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities

Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities
Trendline Trendline
Gilead Sciences Extends Tender Offer for Arcellx Amid Biotech M Challenges

Gilead Sciences Extends Tender Offer for Arcellx Amid Biotech M Challenges

Gilead Sciences Extends Tender Offer for Arcellx Amid Biotech M Challenges
Trendline Trendline
Gilead Extends Tender Offer for Arcellx Amid Biotech M Challenges

Gilead Extends Tender Offer for Arcellx Amid Biotech M Challenges

Gilead Extends Tender Offer for Arcellx Amid Biotech M Challenges
Trendline Trendline
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding Treatment Options for Prader-Willi Syndrome

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding Treatment Options for Prader-Willi Syndrome

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding Treatment Options for Prader-Willi Syndrome
Trendline Trendline
Neurocrine Biosciences Acquires Soleno Therapeutics in $2.9 Billion Deal, Expanding Rare Disease Portfolio

Neurocrine Biosciences Acquires Soleno Therapeutics in $2.9 Billion Deal, Expanding Rare Disease Portfolio

Neurocrine Biosciences Acquires Soleno Therapeutics in $2.9 Billion Deal, Expanding Rare Disease Portfolio
Trendline Trendline
ABION's ABN202 Shows Promise in Overcoming Resistance in Cancer Treatment

ABION's ABN202 Shows Promise in Overcoming Resistance in Cancer Treatment

ABION's ABN202 Shows Promise in Overcoming Resistance in Cancer Treatment